FDC Limited reported a 5.5% year-on-year increase in consolidated net profit to ₹281 crore for the financial year ended March 31, 2026. The board approved the audited standalone and consolidated financial results at a meeting held on May 27, 2026. M/s. BSR & Co. LLP, the Statutory Auditors, issued an unmodified opinion on the results. For the quarter ended March 31, 2026, consolidated net profit surged 167.4% to ₹103 crore, driven by robust revenue growth and enhanced operational efficiencies.

Q4 and Annual Performance

Q4 FY26 revenue from operations stood at ₹585 crore, a robust increase of 18.9% compared to ₹492 crore in the corresponding quarter of the previous year. For the full year, revenue from operations increased to ₹2,171 crore from ₹2,108 crore in FY25. EBITDA for Q4 FY26 stood at ₹106 crore, with margins expanding to 18.2% from 11.0% in the prior year. FY26 EBITDA margin improved to 15.9% from 15.4% year-on-year, driven by higher gross margins.

The following table summarizes FDC's key consolidated financial metrics for Q4 and FY26:

Operational Highlights

All three business segments achieved healthy growth during the quarter. Domestic Formulations business grew by 8.5%, Export Formulations business grew by 99.3%, and the API business grew by 38.6%. The US business overcame earlier challenges to deliver strong performance, with revenue from supplies standing at ₹71 crore, reflecting a year-on-year growth of 165.1%. Overall US business revenue grew 46.9% year-on-year, supported by improved profit share from US partners.

Business Segment Performance

Domestic Formulations revenue stood at ₹452 crore in Q4 FY26. For FY26, sales were ₹1,781 crore, displaying a muted growth of 0.1% compared to the corresponding period last year due to subdued performance in top brands like Zifi, Electral, and Enerzal. Export Formulations sales stood at ₹89 crore in Q4 FY26. During the quarter, the company received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg, and 200mg. API business registered sales of ₹42 crore in Q4 FY26, up by 38.6% year-on-year, and recorded sales of ₹121 crore for FY26.

FDC Limited has appointed Mr. Kishore Mukund Saletore as an Independent Director after shareholders approved the proposal through a postal ballot. The resolution received 99.76% votes in favour, with 127,475,844 shares supporting the appointment against 292,160 shares opposing it. The remote e-voting process commenced on April 28, 2026, and concluded on May 27, 2026.

The appointment was approved via a special resolution under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sanjay Dholakia, Practicing Company Secretary and Proprietor of M/s. Sanjay Dholakia & Associates, served as the scrutinizer for the e-voting process. The record date for determining shareholder eligibility was April 17, 2026.

Voting Results Summary

The following table details the voting pattern across different shareholder categories:

Procedural Details

The postal ballot notice was sent to members whose names appeared in the Register of Members as on the cut-off date of April 17, 2026. The e-voting module, provided by NSDL, was disabled on May 27, 2026, at 5:00 p.m., following which the scrutinizer unblocked the votes in the presence of two witnesses not employed by the company. The scrutinizer's report confirms that the special resolution was passed with the requisite majority.

The electronic data and relevant records relating to the remote e-voting have been handed over to Ms. Varsharani Katre, Company Secretary and Compliance Officer of FDC Limited, for safe custody. The appointment is effective from the date of passing the resolution, May 27, 2026.